#United States #San Francisco #Hagens Berman #Inspire Medical #INSP

Inspire Medical Faces Major Setbacks: A Closer Look

In a striking recent development, Inspire Medical Systems, Inc. (NYSE: INSP) has witnessed a staggering 32% decline in its stock prices, following significant issues related to the Inspire V device launch. The law firm Hagens Berman, known for defending shareholder rights, has stepped into the fray, urging affected investors to come forward and explore potential legal recourse against the company. The deadline for stakeholders to participate in a class action lawsuit is set for January 5, 2026.

The Allegations

The core of the allegations against Inspire Medical revolves around claims of misleading information presented to investors. According to the lawsuit, Inspire Medical's management issued assurances regarding their preparedness for the Inspire V launch, stating they were “ready to throw the switch.” However, it appears that critical software failures—specifically concerning billing protocols with Medicare—and insufficient training efforts led to an operational reality far different from these promises.

The lawsuit indicates that these undisclosed failures culminated in an 80% reduction in EPS guidance, thus prompting an alarming drop in stock value. Partner Reed Kathrein from Hagens Berman has been pivotal in analyzing these discrepancies, stating, “Our investigation centers on the purported disconnect between management's claims… and the alleged undisclosed operational reality.”

A Closer Examination of the Operational Hurdles

The lawsuit emphasizes several key areas where Inspire Medical allegedly failed to meet necessary standards of disclosure:

1. Billing Reimbursement Issues: The management reportedly stated that their billing policies were up-to-date for prompt payments. However, they concealed the fact that critical software updates necessary for Medicare claims processing wouldn’t be active until July 1, 2025, effectively blocking any reimbursement for procedures and inevitably stalling the adoption of the Inspire V device.

2. Concealed Sales Practices: Additionally, it is alleged that the company failed to inform investors about the significant surplus inventory of the earlier model, Inspire IV, which stifled demand for the new product. The undisclosed channel inventory issues may have misled investors regarding actual sales numbers and the future earnings potential associated with Inspire V.

3. Drastic Financial Impacts: The repercussions for investors have been profound. Following the admission of operational setbacks and the subsequent guidance adjustment, the stock price plummeted by $42.04 per share, resulting in noteworthy financial losses for shareholders.

Legal Framework and Moving Forward

The class action lawsuit targets individuals who acquired Inspire Medical’s securities between August 6, 2024, and August 4, 2025. Those who believe they have suffered losses as a result of alleged misinformation are encouraged to reach out to Hagens Berman.

Hagens Berman has a notable track record, having amassed over $325 billion in settlements in similar cases, underscoring their commitment to fighting for investor rights.

Investors are also pointed towards potential whistleblower options. Those with undisclosed information regarding Inspire Medical’s operational failures may have the opportunity to contribute to the case and could be eligible for rewards from the SEC's Whistleblower program.

Conclusion

Inspire Medical's challenging circumstances highlight the precarious balance between corporate assurance and operational reality. Investors currently faced with losses stemming from the Inspire V launch failures are urged to consider their legal rights swiftly. The January 5 deadline looms large, making it imperative for shareholders to act quickly and inform themselves of their options.